Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Cantor Fitzgerald Raises Ascendis Pharma (ASND) PT to $254, Sees Steady New Patient Adds
-
Ascendis Pharma (ASND) PT Raised to $203 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Ascendis Pharma (ASND) PT Raised to $200 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh
-
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
-
Ascendis Pharma (ASND) Prices 4.225M ADS Offering at $14/ADS
-
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) Prices 4.166M ADS Offering at $120/ADS
-
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
-
Ascendis Pharma (ASND) PT Raised to $185 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Ascendis Pharma (ASND) at Overweight
-
Pre-Open Movers 09/22: (ASND) (SVRA) (S) Higher; (VSAR) (ICPT) (FINL) Lower (more...)
